Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Smith & Nephew Snats (NPWA) Stock Price & Analysis

2 Followers

NPWA Stock Chart & Stats

€27.60-€0.20(-2.82%)
At close: 5:30 PM GMT+1
€25€26€27Jun 15Jul 1Jul 22Jul 31Sep 4
Day’s Range
EUR 27.60 - EUR 27.60
52-Week Range
EUR 23.00 - EUR 31.20
Previous Close
EUR 28.40
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 11.39B
Enterprise Value
EUR 15.98B
Total Cash (Recent Filing)
EUR 754.00M
Total Debt (Recent Filing)
EUR 3.79B
Price to Earnings (P/E)
20.0
Beta
0.67
Next Earnings
Mar 01, 2027 (Est.)
EPS Estimate
0.59
Next Dividend Ex-Date
N/A
Dividend Yield
2.50%

Bulls Say, Bears Say

Bulls Say

Margin And Cash-flow Recovery

Improving margins and strong cash generation indicate that efficiency actions are translating into more durable earnings quality. Maintaining profit, free cash flow, and ROIC targets despite slower revenue growth gives the company resources to fund innovation, investment, and shareholder returns.

Sports Medicine Growth

Strong Sports Medicine and ENT performance provides a meaningful growth engine that can offset weakness in other franchises. Broad demand and double-digit platform growth suggest product-market traction, while procedure-linked consumables can support repeat revenue as adoption expands.

Product And Innovation Pipeline

Continued regulatory progress and product launches strengthen the portfolio across surgery and wound care. A broader offering can help close orthopaedic portfolio gaps, improve competitiveness with providers, and create additional avenues for growth as new systems and consumables ramp.

Bears Say

Slowing Revenue Growth

Lower revenue momentum limits near-term operating leverage and makes the company more dependent on cost savings to deliver earnings growth. The revised outlook also indicates that portfolio improvements and demand recovery may take longer to translate into broad-based sales acceleration.

U.S. Orthopaedics Weakness

Weakness in U.S. knees and hips affects a strategically important franchise and exposes gaps in the current product offering. Delayed deployments and the need for new launches can defer recovery, while continued underperformance may pressure market position and overall growth.

Wound-care Reimbursement Pressure

Reimbursement changes and billing friction create a structural challenge for skin substitutes and bioactives rather than a simple volume issue. They can reduce product economics, slow customer adoption, and require market adaptation before wound-care growth and profitability normalize.

Smith & Nephew Snats News

NPWA FAQ

What was Smith & Nephew Snats’s price range in the past 12 months?
Smith & Nephew Snats lowest stock price was €23.00 and its highest was €31.20 in the past 12 months.
What is Smith & Nephew Snats’s market cap?
Smith & Nephew Snats’s market cap is €11.39B.
When is Smith & Nephew Snats’s upcoming earnings report date?
Smith & Nephew Snats’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 109 days.
How were Smith & Nephew Snats’s earnings last quarter?
Smith & Nephew Snats released its earnings results on Aug 04, 2026. The company reported €0.385 earnings per share for the quarter, missing the consensus estimate of €0.841 by -€0.456.
Is Smith & Nephew Snats overvalued?
According to Wall Street analysts Smith & Nephew Snats’s price is currently Undervalued.
Does Smith & Nephew Snats pay dividends?
Smith & Nephew Snats does not currently pay dividends.
What is Smith & Nephew Snats’s EPS estimate?
Smith & Nephew Snats’s EPS estimate is 0.59.
How many shares outstanding does Smith & Nephew Snats have?
Smith & Nephew Snats has 418,717,070 shares outstanding.
What happened to Smith & Nephew Snats’s price movement after its last earnings report?
Smith & Nephew Snats reported an EPS of €0.385 in its last earnings report, missing expectations of €0.841. Following the earnings report the stock price went up 1.447%.
Which hedge fund is a major shareholder of Smith & Nephew Snats?
Hedge funds hold Smith & Nephew Snats shares: the largest hedge-fund position in Smith & Nephew Snats is 1,967,103,398 shares, and hedge funds increased their holdings by 1.4M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology